

Kaufman, Claire

From: Kaufman, Claire
Sent: Wednesday, August 13, 2003 10:50 AM
To: STIC-Biotech/ChemLib
Subject: sequence search 09/990,940

SEQUENCE SEARCH REQUEST

NAME: CLAIRE KAUFMAN AU: 1646 MAILBOX: 10D19

SERIAL NUMBER: **09/990,940** DATE: 8/13/03

Please search SEQ ID NO:17 and 18 and
oligo search both 17 and 18 (I need 50 contiguous amino acids or 100 contiguous
nucleotides). Please search in commercial and interference database.

Please put results on disk.

Thanks!

Claire Kaufman
AU 1646, 305-5791

```

AC      Q8BHH0; PRELIMINARY;          PRT;          365 AA
DT      01-MAR-2003 (TrEMBLrel. 23, Created)
DT      01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT      01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
5  DE      Hypothetical rhodopsin-like GPCR superfamily containing protein.
OS      Mus musculus (Mouse).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX      NCBI_TaxID=10090;
10 RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=C57BL/6J; TISSUE=Dorsal root ganglion, and Head;
RX      MEDLINE=22354683; PubMed=12466851;
RA      The FANTOM Consortium,
15 RA      the RIKEN Genome Exploration Research Group Phase I & II Team;
RT      "Analysis of the mouse transcriptome based on functional annotation of
RT      60,770 full-length cDNAs.";
RL      Nature 420:563-573(2002).
DR      EMBL; AK048439; BAC33337.1; -.
20 DR      EMBL; AK051723; BAC34735.1; -.
KW      Hypothetical protein.
SQ      SEQUENCE      365 AA;  41759 MW;  1EB7E5369632ED56 CRC64;

      Query Match          88.2%;  Score 1905;  DB 11;  Length 365;
25      Best Local Similarity 100.0%;  Pred. No. 8.6e-160;
      Matches 365;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0

Qy      52 MLIFALALFGNALVVYVTRSKAMRTVTNIFICSLALSDLLIVFFCIPVTMLQNVSDTWL 111
      |||
30 Db      1 MLIFALALFGNALVVYVTRSKAMRTVTNIFICSLALSDLLIVFFCIPVTMLQNVSDTWL 60

Qy      112 GGAFICKMVPFVQCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWL 171
      |||
Db      61 GGAFICKMVPFVQCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWL 120

35 Qy      172 AIIIGSPMWHVQRLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSV 231
      |||
Db      121 AIIIGSPMWHVQRLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSV 180

40 Qy      232 LYGKIGYELWIKKRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIV 291
      |||
Db      181 LYGKIGYELWIKKRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIV 240

Qy      292 HMMIEYSNFEKEYDEVTIKMIFAIVQIIGFFNSICNPPIIYALMNENFKKNFVSAVCYCIV 351
      |||
45 Db      241 HMMIEYSNFEKEYDEVTIKMIFAIVQIIGFFNSICNPPIIYALMNENFKKNFVSAVCYCIV 300

Qy      352 KETPSSARKHGSSGAMVMHRRAKLAARENPVEIKGEAFGGSNIDIKWCEQPEKKKRRSKV 411
      |||
50 Db      301 KETPSSARKHGSSGAMVMHRRAKLAARENPVEIKGEAFGGSNIDIKWCEQPEKKKRRSKV 360

Qy      412 ASCPL 416
      ||||
Db      361 ASCPL 365

```

Art Unit: 1646

SEQUENCE COMPARISON A

AC AAB02853;
XX
DT 22-AUG-2000 (first entry)
XX
5 DE Human G protein coupled receptor hRUP4 (V272K) protein SEQ ID NO:128.
XX
KW Human; G protein coupled receptor; GPCR; transmembrane receptor;
KW identification; agonist; screening; therapeutic; pharmaceutical;
KW mutant.
10 XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200022131-A2.
15 XX
PD 20-APR-2000.
XX
PF 13-OCT-1999; 99WO-US24065.
XX
20 PR 13-OCT-1998; 98US-0170496.
PR 12-NOV-1998; 98US-0108029.
PR 20-NOV-1998; 98US-0109213.
PR 27-NOV-1998; 98US-0110060.
PR 16-FEB-1999; 99US-0120416.
25 PR 26-FEB-1999; 99US-0121852.
PR 12-MAR-1999; 99US-0123944.
PR 12-MAR-1999; 99US-0123945.
PR 12-MAR-1999; 99US-0123946.
PR 12-MAR-1999; 99US-0123948.
30 PR 12-MAR-1999; 99US-0123949.
PR 12-MAR-1999; 99US-0123951.
PR 28-MAY-1999; 99US-0136436.
PR 28-MAY-1999; 99US-0136437.
PR 28-MAY-1999; 99US-0136439.
35 PR 28-MAY-1999; 99US-0137127.
PR 28-MAY-1999; 99US-0137131.
PR 28-MAY-1999; 99US-0137567.
PR 30-JUN-1999; 99US-0141448.
PR 27-AUG-1999; 99US-0151114.
40 PR 03-SEP-1999; 99US-0152524.
PR 29-SEP-1999; 99US-0156633.
PR 29-SEP-1999; 99US-0156555.
PR 29-SEP-1999; 99US-0156634.
XX
45 PA (AREN-) ARENA PHARM INC.
XX
PI Behan DP, Lehmann-Bruinsma K, Chalmers DT, Chen R, Dang HT;
PI Gore M, Liaw CW, Lin I, Lowitz K, White C;
XX
50 DR WPI; 2000-317986/27.
DR N-PSDB; AAA46115.
XX
PT Non-endogenous, human G protein-coupled receptors for screening
PT receptor, inverse or partial agonists useful as therapeutic agents -

Art Unit: 1646

XX

PS Example 2; Page 164-166; 187pp; English.

XX

5 CC The present invention describes transmembrane receptors, preferably
CC human G protein coupled receptors (GPCR), for which the endogenous
CC ligand is unknown (orphan GPCR receptors). More specifically the present
CC invention relates to non-endogenous, constitutively activated versions
CC of a human GPCR. These non-endogenous human GPCRs can be useful for
10 CC the direct identification of candidate compounds as receptors agonists,
CC inverse agonists or partial agonists for use as pharmaceutical agents.
CC AAA46017 to AAA46126 and AAB02825 to AAB02859 represent sequences used in
CC the exemplification of the present invention.

XX

15 SQ Sequence 431 AA;

Query Match 81.4%; Score 1758; DB 21; Length 431;
Best Local Similarity 79.7%; Pred. No. 1.2e-187;
Matches 337; Conservative 37; Mismatches 39; Indels 10; Gaps
3;

20

Qy 4 NLTAEQLSALLRLHNLTRAQFIAHYGLRPLVLTQPQPARARLALLLVGMLIFALALFGNA 63
|:| || | ||| |||| | |||| | :|| | :||| :| :| |||||
Db 5 NITPEQFSRLLRDHNLTREQFIALYRLRPLVYTPELPGRAKLALVLTGVLIFALALFGNA 64

25

Qy 64 LVVYVTRSKAMRTVTNIFICSIALSDLLIVFFCIPVTMLQNVSDTWLGGAFICKMVPFV 123
|| ||||| ||||| ||||| ||||| ||||| :|| ||||| |||||
Db 65 LVFYVTRSKAMRTVTNIFICSIALSDLLITFFCIPVTMLQNISDNWLGGAFICKMVPFV 124

30

Qy 124 QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ 183
| :||| :||| ||||| ||||| ||||| :||| ||||| :||| |||||
Db 125 QSTAVVTEMLTMTCIAVERHQGLVHPFKMKWQYTNRRRAFTMLGVVWLVAIVIGSPMWHVQ 184

35

Qy 184 RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLSVLYGKIGYELWIK 243
:||||| :||||| :||||| :||||| :||||| :||||| :|||||
Db 185 QLEIKYDFLYEKEHICCLEEWTSPPVHQKIYTTFILVILFLLPLMVMLILYSKIGYELWIK 244

40

Qy 244 KRIGDGSVLRITIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHVHMMIEYSNFEKE 303
|| :||| :||| ||||| ||||| ||||| :||| ||||| |||||
Db 245 KRVGDGSVLRITIHGKEMSKIARKKKRAKIMMVTVVALFVAVCWAPFHVHMMIEYSNFEKE 304

45

Qy 304 YDEVTIKMIFAIVQIIGFFNSICNPIIYALMNENFKKNFVSAVCYCIVKETPSSARKHGS 363
|| :||| :||| ||||| :||| ||||| :||| ||||| :||| :|||
Db 305 YDDVTIKMIFAIVQIIGFSNSICNPIVYAFMNENFKKNVLSAVCYCIVNKTFSQAQRHGN 364

50

Qy 364 SGAMVMHRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKK-----RSKVA-S 413
|| :| :|| : |||| | |||| | :|| ||| :||| :||| :
Db 365 SGITMMRKKAKFSLRENPEETKGEAFSDGNIEVKLCEQTEKKKKLKRHLALFRSELAEN 424

Qy 414 CPL 416

||

Db 425 SPL 427

SEQUENCE COMPARISON- 13

neuropeptide Y/peptide YY receptor Y2 - human
 N;Alternate names: neuropeptide y/peptide YY receptor type 2
 C;Species: Homo sapiens (man)
 C;Date: 01-Mar-1996 #sequence_revision 01-Mar-1996 #text_change 20-Apr-2000
 5 C;Accession: I39187; I39163; G02301
R;Gerald, C.; Walker, M.W.; Vaysse, P.J.
J. Biol. Chem. 270, 26758-26761, 1995
 A;Title: Expression cloning and pharmacological characterization of a human
 hippocampal neuropeptide Y/peptide YY Y2 receptor subtype.
 10 A;Reference number: I39187; MUID:96070760; PMID:7592910
 A;Accession: I39187
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-381 <GER>
 15 A;Cross-references: EMBL:U36269; NID:g1063633; PIDN:AAC50281.1; PID:g1063634
R;Rose, P.M.; Fernandes, P.; Lynch, J.S.; Frazier, S.T.; Fisher, S.M.;
Kodukula, K.; Kienzle, B.; Seethala, R.
J. Biol. Chem. 270, 22661-22664, 1995
 A;Title: Cloning and functional expression of a cDNA encoding a human type 2
 20 neuropeptide Y receptor.
 A;Gene: GDB:NPY2R
 A;Cross-references: GDB:4365607; OMIM:162642
 A;Map position: 4q31-4q31
 C;Superfamily: neurokinin 1 receptor
 25 F;49-76/Domain: transmembrane #status predicted <TM1>
 F;87-113/Domain: transmembrane #status predicted <TM2>
 F;166-186/Domain: transmembrane #status predicted <TM4>
 F;221-237/Domain: transmembrane #status predicted <TM5>
 F;269-291/Domain: transmembrane #status predicted <TM6>
 30 F;305-328/Domain: transmembrane #status predicted <TM7>
 F;123-203/Disulfide bonds: #status predicted
 F;342/Binding site: palmitate (Cys) (covalent) #status predicted
 F;372/Binding site: carbohydrate (Asn) (covalent) #status predicted
 35 Query Match 20.5%; Score 442; DB 2; Length 381;
 Best Local Similarity 30.7%; Pred. No. 3.7e-30;
 Matches 96; Conservative 77; Mismatches 106; Indels 34; Gaps
 9;
 40 Qy 44 RLALLLVGMLIFALALFGNALVVYVTRSKAMRTVTNIFICSIALSDLLIVFFCIPVTML 103
 :: ||: | | : ||: ||: || : | : || || || | : ||: ||: | : | | :
 Db 50 QVVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLT 109
 Qy 104 QNVSDTWLGGAFICKMVPFVQCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFT 163
 45 : | | : | : ||: | | : : ||: ||: ||: | : : : : : : |
 Db 110 YTLMGEWKMGVPLCHLVPYAQGLAVQVSTITLTVIALDRHRCIV--YHLESKISKRISFL 167
 Qy 164 MLGVVWLVAIIIGSPM---WHVQRLEIKYDFLYEKEHICCLEEW---SSPVHQKIYTTFI 217
 :: ||: | : : : ||: : || || | : | ||: : : : | :
 50 Db 168 IIGLAWGISALLASPLAIFREYSLIEIIPDF----EIVACTEKWPGEEKSIYGTVYSLSS 223
 Qy 218 LVTFLLLPLLLLSVLYGKIGYELW--IKKRIGDGSVLRTIHGKEMFKIARKKKRAVIMMV 275
 | : ||: || ||: | : | | : | : | : : : : : | : |
 Db 224 LLILYVLPGLGIISFSYTRI----WSKLNHVSPGAANDHYH-----QRRQKTTKMLV 271
 55 Qy 276 TVVVLFAVCWAPFHIVHMMIEYSNFE---KEYDEVTIKMIFAIVQIIGFFNSICNPIIYA 332
 |||: ||| | | : : : ||| | : || : || : : ||: ||:

Db 272 CVVVVFAVSWLPLHAFQLAVDIDSQVLDLKEY-----KLIFTVFHIIAMCSTFANPLLYG 326

Qy 333 LMNENFKKNFVSA 345 8/9=88% identical
|| |::| |::|

5 Db 327 WMNSNYRKAFLSA 339

SEQUENCE COMPARISON - C

```

AC      Q8BHH0; PRELIMINARY;          PRT;   365 AA
DT      01-MAR-2003 (TrEMBLrel. 23, Created)
DT      01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT      01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
5  DE      Hypothetical rhodopsin-like GPCR superfamily containing protein.
OS      Mus musculus (Mouse).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX      NCBI_TaxID=10090;
10  RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=C57BL/6J; TISSUE=Dorsal root ganglion, and Head;
RX      MEDLINE=22354683; PubMed=12466851;
RA      The FANTOM Consortium,
15  RA      the RIKEN Genome Exploration Research Group Phase I & II Team;
RT      "Analysis of the mouse transcriptome based on functional annotation of
RT      60,770 full-length cDNAs.";
RL      Nature 420:563-573(2002).
DR      EMBL; AK048439; BAC33337.1; -.
20  DR      EMBL; AK051723; BAC34735.1; -.
KW      Hypothetical protein.
SQ      SEQUENCE      365 AA;  41759 MW;  1EB7E5369632ED56 CRC64;

```

```

25      Query Match      88.2%;  Score 1905;  DB 11;  Length 365;
      Best Local Similarity 100.0%;  Pred. No. 8.6e-160;
      Matches 365;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0

```

30	Qy	52	MLIFALALFGNALVVYVVT	RSKAMRTVTNIFICS	LALSDLLIVFFCIPVTMLQNVSDTWL	111
	Db	1	MLIFALALFGNALVVYVVT	RSKAMRTVTNIFICS	LALSDLLIVFFCIPVTMLQNVSDTWL	60
35	Qy	112	GGAFICKMVPFVQCTAIVTEIL	TMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWL	171	
	Db	61	GGAFICKMVPFVQCTAIVTEIL	TMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWL	120	
40	Qy	172	AIIGSPMWHVQRLEIKYDFLYEKEHIC	CLEEWSSPVHQKIYTTFILVTLFLLPLLLLSV	231	
	Db	121	AIIGSPMWHVQRLEIKYDFLYEKEHIC	CLEEWSSPVHQKIYTTFILVTLFLLPLLLLSV	180	
45	Qy	232	LYGKIGYELWIKKRIGDGSVLR	TIHGKEMFKIARKKKRAVIMMVTVVVLFAVCWAPFHIV	291	
	Db	181	LYGKIGYELWIKKRIGDGSVLR	TIHGKEMFKIARKKKRAVIMMVTVVVLFAVCWAPFHIV	240	
50	Qy	292	HMMIEYSNFEKEYDEVTIKMIFAIVQ	IIGFFNSICNPIIYALMNENFKKNFVS	351	
	Db	241	HMMIEYSNFEKEYDEVTIKMIFAIVQ	IIGFFNSICNPIIYALMNENFKKNFVS	300	
55	Qy	352	KETPSSARKHGSSGAMVMHRRAKLA	ARENPVEIKGEAFGGSNIDIKWCEQPEKKKRRSKV	411	
	Db	301	KETPSSARKHGSSGAMVMHRRAKLA	ARENPVEIKGEAFGGSNIDIKWCEQPEKKKRRSKV	360	
60	Qy	412	ASCPL	416		
	Db	361	ASCPL	365		

Art Unit: 1646

11 CPL 116
425 SPL 427

SEQUENCE COMPARISON - D

5

10 AC AAY71309;
XX
DT 02-NOV-2000 (first entry)
XX
DE Human orphan G protein-coupled receptor hRUP4.
XX
15 KW Human; orphan G protein-coupled receptor; GPCR; hRUP4; drug screening;
KW transmembrane receptor; expressed sequence tag; EST; signal cascade.
XX
OS Homo sapiens.
XX
20 PN WO200031258-A2.
XX
PD 02-JUN-2000.
XX
PF 13-OCT-1999; 99WO-US23687.
25 XX
PR 20-NOV-1998; 98US-0109213.
PR 16-FEB-1999; 99US-0120416.
PR 26-FEB-1999; 99US-0121852.
PR 12-MAR-1999; 99US-0123946.
30 PR 12-MAR-1999; 99US-0123949.
PR 28-MAY-1999; 99US-0136436.
PR 28-MAY-1999; 99US-0136437.
PR 28-MAY-1999; 99US-0136439.
PR 28-MAY-1999; 99US-0136567.
35 PR 28-MAY-1999; 99US-0137127.
PR 28-MAY-1999; 99US-0137131.
PR 29-JUN-1999; 99US-0141448.
PR 29-SEP-1999; 99US-0156555.
PR 29-SEP-1999; 99US-0156633.
40 PR 29-SEP-1999; 99US-0156634.
PR 29-SEP-1999; 99US-0156653.
PR 01-OCT-1999; 99US-0157280.
PR 01-OCT-1999; 99US-0157281.
PR 01-OCT-1999; 99US-0157282.
45 PR 01-OCT-1999; 99US-0157293.
PR 01-OCT-1999; 99US-0157294.
PR 12-OCT-1999; 99US-0416760.
PR 12-OCT-1999; 99US-0417044.
XX
50 PA (AREN-) ARENA PHARM INC.
XX
PI Chen R, Dang HT, Liaw CW, Lin I;
XX
DR WPI; 2000-400068/34.

DR N-PSDB; AAD01136.

XX

XX

PS Claim 74; Page 89-91; 102pp; English.

XX

The present amino acid sequence is the hRUP4, an endogenous human orphan G protein-coupled receptor (GPCR). The full length hRUP4 cDNA was cloned by RT-PCR with human brain cDNA as template. The hRUP4 PCR fragment obtained was an alternatively spliced form of the EST (expressed sequence tag) clone AI307658. The orphan GPCR of the invention, like all GPCRs has seven transmembrane alpha helices with an extracellular N-terminus and an intracellular C-terminus. However, no endogenous ligands has yet been identified for the proteins of the invention. The orphan GPCRs may be used in the identification of their endogenous ligands, and to screen potential GPCR agonists and antagonists for use as pharmaceutical agents. The proteins may also be used in the study of GPCR-mediated signalling cascades, and to elucidate their precise role in normal and diseased human conditions. Nucleic acid encoding human orphan GPCRs may be used for tissue localisation expression analysis to provide information about their function in healthy and pathological states.

XX

SO Sequence 431 AA;

Query Match 81.7%; Score 1764; DB 21; Length 431;
Best Local Similarity 79.9%; Pred. No. 2.5e-188;
Matches 338; Conservative 37; Mismatches 38; Indels 10; Gaps

3:

Qy 4 NLTAEQLSALLRLHNLTRAQFIAHYGLRPLVLTPQLPARARLALLLVGMLIFALALFGNA 63
| : | | | | | | | | | | | | | | | | : | | : | | : | | | | | | | |
Db 5 NITPEOFSRLLRDHNLTREOFIALYRLRPLVYTPELPGRAKLALVLTGVLIFALALFGNA 64

Qy 64 LVVYVWTRSKAMRTVTNIFICSLALSDLLIVFFCIPVTMLQNVS DTLGGA FICKMVPFV 123
|| ||||| : || |||||

Db 65 LVFYVWTRSKAMRTVTNIFICSLALSDLLITFFCIPVTMLONISDNWLGGAFICKMVPFV 124

Qy 124 QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ 183
| ||:||||:||||||| ||||| |||:|||||||:|:|||||||

Db 125 OSTAVVTEMLTMTCIAVERHQGLVHPFKMKWOYTNBRAFTMLGVVWLVAIVIGSPMWHVO 184

```
Qy      184 RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFFILVTLFLLPLLLLLSVLYGKIGYELWIK 243
        :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      185 QLEIKYDELYEKEHICCLEEWTSVPVHOKIYTTFFILVILELPLMVMLILYSKIGYELWIK 244
```

Qy 244 KRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIHVHMMIEYSNFEKE 303
 ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 245 KRVGDGSVLRTIHGKEMSKIARKKKRAVIMMVTVVALFAVCWAPFHVHMMIEYSNFEKE 304

QY 304 YDEVTIKMI FAIVQII GFFNSICNPIIYALMNENFKKNFVSAVCYCIVKETPSSARKHGS 363
||:|||||:|||||:| ||||| :||||| :|| |:|:

Db 305 YDDVTIKMI FAIVQII GFSNSICNPIVYAEMNENFKKNVLSAVCYCIVNKTFSAPORHGN 364

Art Unit: 1646

Qy 364 SGAMVMHRRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKKR-----RSKVA-S 413
|| :| ::|| : ||||| | ||||| ||::| || |::|| : ||::| :

Db 365 SGITMMRKKAKFSLRENPVETKGEAFSDGNIEVKLCEQTEEKKKLKRHLALFRSELAEN 424

5 Qy 414 CPL 416

||
Db 425 SPL 427

SEQUENCE COMPARISON - B

Qy 218 LVTFLLLPLLLLLSVLYGKIGYELW--IKKRIGDGSVLRITIHGKEMFKIARKKKRAVIMMV 275
 | : | ::||| ::| | :| | : | : | : | : | : | : | : |

Db 224 LLILYVLPLGIISFSYTRI----WSKLKNHVSPGAANDHYH-----QRRQKTTKMLV 271

Qy 276 TVVVLFAVCWAPFHIVHMMIEYSNFE---KEYDEVTIKMIFAIVQIIGFFNSICNPIIYA 332

5 Db 272 CVVVVFAVSWLPLHAFQLAVDIDSQVLDLKEY-----KLIFTVFHIIAMCSTFANPLLYG 326

Qy 333 LMNENFKKNFVSA 345 8/9=88% identical

10 Db 327 WMNSNYRKAFLSA 339

Art Unit: 1646

AC AAY94993;
XX
DT 19-JUN-2000 (first entry)
5 XX
DE Human secreted protein vc38_1, SEQ ID NO:26.
XX
KW Human; secreted protein; cancer; tumour; cardiovascular disorder;
KW blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
10 KW infection; fungal; bacterial; viral; HIV; allergy; arthritis;
KW neurodegenerative disease; asthma; contraceptive.
XX
OS Homo sapiens.
XX
15 PN WO200011015-A1.
XX
PD 02-MAR-2000.
XX
PF 24-AUG-1999; 99WO-US19351.
20 XX
PR 24-AUG-1998; 98US-0097638.
PR 24-AUG-1998; 98US-0097659.
PR 09-SEP-1998; 98US-0099618.
PR 28-SEP-1998; 98US-0102092.
25 PR 25-NOV-1998; 98US-0109978.
PR 23-DEC-1998; 98US-0113645.
PR 23-DEC-1998; 98US-0113646.
PR 23-AUG-1999; 99US-0379246.
XX
30 PA (ALPH-) ALPHAGENE INC.
XX
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR WPI; 2000-224657/19.
35 XX
PT New secreted or transmembrane proteins and polynucleotides encoding
PT them, useful for treating neurodegenerative disorders, autoimmune
PT diseases and cancer -
XX
40 PS Claim 35; Page 284-285; 357pp; English.
XX
CC The invention relates to 40 human secreted proteins (AAY94981-Y95020),
CC and cDNA sequences encoding them (AAA23423-A23462). The secreted
CC proteins of the invention include those that are thought to be only
45 CC partially secreted, i.e., transmembrane proteins. The proteins of the
CC invention may exhibit one or more activities selected from the following:
CC cytokine activity; cell proliferation; differentiation; immune
CC modulation; haematopoiesis regulation; tissue growth activity;
CC activin/inhibin activity; chemotactic/chemokinetic activity; haemostatic
50 CC and thrombolytic activity; anti-inflammatory activity; and tumour
CC inhibition activity. The proteins may be administered to patients as
CC vaccines, and the nucleotides may be used as part of a gene therapy

CC regime. Diseases or conditions that may be treated using the proteins or
CC nucleotides of the invention include autoimmune diseases; genetic
CC disorders; haemophilia; cardiovascular diseases; cancer; bacterial,
CC fungal and viral infections, especially HIV; multiple sclerosis;
5 CC rheumatoid arthritis; pulmonary inflammation; Guillain-Barre syndrome;
CC insulin dependent diabetes mellitus; and allergic reactions such as
CC asthma and anaemia. They may also be used for treating wounds, burns,
CC ulcers, osteoporosis, osteoarthritis, periodontal diseases, Alzheimer's
CC disease, Parkinson's disease, Huntington's disease and amyotrophic
10 CC lateral sclerosis (ALS). Proteins with activin/inhibin activity may
CC additionally be useful as contraceptives. Nucleic acid sequences of the
CC invention may be used in chromosome mapping, and as a source of
CC diagnostic primers and probes. The present sequence represents one of the
CC 40 proteins of the invention.

15 XX
SQ Sequence 431 AA;

Query Match 81.8%; Score 1767; DB 21; Length 431;
Best Local Similarity 80.1%; Pred. No. 1.2e-188;
Matches 339; Conservative 36; Mismatches 38; Indels 10; Gaps
;

25	Qy	4	NLTAEQLSALLRLHNLTRAQFIAHYGLRPLVLTPQLPARARLALLLVGMLIFALALFGNA	63
	Db	5	NITPEQFSRLLRDHNLTREQFIALYRLRPLVYTPELPGRAKLALVLTGVLIIFALALFGNA	64
30	Qy	64	LVVYVTRSKAMRTVTNIFICSLALSDDLIVFFCIPVTMLQNVSDTWLGGAFIGKMPVFPV	123
	Db	65	LVFYVTRSKAMRTVTNIFICSLALSDDLITFFCIPVTMLQNISDNWLGGAFIGKMPVFPV	124
35	Qy	124	QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ	183
	Db	125	QSTAVVTEILTMTCIAVERHQGLVHPFKMKWQYTNRRRAFTMLGVVWLVAIVIGSPMWHVQ	184
40	Qy	184	RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSVLYGKIGYELWIK	243
	Db	185	QLEIKYDFLYEKEHICCLEEWTSPPVHQKIYTTFILVILFLLPLMVMLILYISKIGYELWIK	244
45	Qy	244	KRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIVHMMIEYSNFEKE	303
	Db	245	KRVGDGSVLRTIHGKEMSKIARKKKRAVIMMVTVVVLFVAVCWAPFHVHMMIEYSNFEKE	304
50	Qy	304	YDEVTIKMIFAIVQIIGFFNSICNPIIYALMNENFKKNFVSACVYCIKTPSSARKHGS	363
	Db	305	YDDVTIKMIFAIVQIIGFSNSICNPVYAFMNENFKKNVLSACVYCIKNKTFSPAQRHGN	364
55	Qy	364	SGAMVMHRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKKR-----RSKVA-S	413
	Db	365	SGITMMRKKAKFSLRENPEETKGEAFSDGNIEVKLCEQTEKKKKLRHLALFRSELAEN	424
60	Qy	414	CPL 416	
	Db	425	SPL 427	

AC Q9Z2D5;
5 DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor).
GN NPY2R.
10 OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
15 RP SEQUENCE FROM N.A.
RX MEDLINE=99017376; PubMed=9802390;
RA Sharma P.S., Holmberg S.K., Eriksson H., Beck-Sickinger A.G.,
RA Grundemar L., Larhammar D.;
RT "Cloning and functional expression of the guinea pig neuropeptide Y
20 RT Y2 receptor.";
RL Regul. Pept. 75:23-28(1998).
CC -!- FUNCTION: RECEPTOR FOR NEUROPEPTIDE Y AND PEPTIDE YY.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.
25 CC HIGHEST TO TACHYKININS RECEPTORS.
CC -----
CC -
CC This SWISS-PROT entry is copyright. It is produced through a
collaboration
30 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC -
CC the European Bioinformatics Institute. There are no restrictions on
its
CC use by non-profit institutions as long as its content is in no
35 CC way
CC modified and this statement is not removed. Usage by and for
commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
40 CC or send an email to license@isb-sib.ch).
CC -----
CC -
DR EMBL; AF072821; AAD13143.1; -.
DR InterPro; IPR000276; GPCR_Rhodpsn.
45 DR Pfam; PF00001; 7tm_1; 1.
DR PRINTS; PR00237; GPCRRHODOPSN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
KW G-protein coupled receptor; Transmembrane; Glycoprotein;
50 KW Phosphorylation; Lipoprotein; Palmitate.

```

FT      DOMAIN          1       50      EXTRACELLULAR (POTENTIAL).
FT      TRANSMEM        51       73      1 (POTENTIAL).
FT      DOMAIN          74       83      CYTOPLASMIC (POTENTIAL).
FT      TRANSMEM        84      105      2 (POTENTIAL).
5 FT      DOMAIN         106      125      EXTRACELLULAR (POTENTIAL).
FT      TRANSMEM       126      147      3 (POTENTIAL).
FT      DOMAIN         148      167      CYTOPLASMIC (POTENTIAL).
FT      TRANSMEM       168      188      4 (POTENTIAL).
FT      DOMAIN         189      215      EXTRACELLULAR (POTENTIAL).
10 FT      TRANSMEM      216      241      5 (POTENTIAL).
FT      DOMAIN         242      269      CYTOPLASMIC (POTENTIAL).
FT      TRANSMEM      270      292      6 (POTENTIAL).
FT      DOMAIN         293      305      EXTRACELLULAR (POTENTIAL).
FT      TRANSMEM      306      329      7 (POTENTIAL).
15 FT      DOMAIN         330      381      CYTOPLASMIC (POTENTIAL).
FT      CARBOHYD        11       11      N-LINKED (GLCNAC. . .) (POTENTIAL).
FT      DISULFID        124      204      BY SIMILARITY.
FT      LIPID           343      343      PALMITATE (POTENTIAL).
SQ      SEQUENCE       381 AA;   42342 MW; D806B859A43ECACE CRC64;

20      Query Match                20.9%; Score 452; DB 1; Length 381;
      Best Local Similarity    31.6%; Pred. No. 4.5e-25;
      Matches 99; Conservative 74; Mismatches 106; Indels 34; Gaps
      9;

25 Qy      44 RLALLLVGMLIFALALFGNALVVYVTRSKAMRTVTNIFICSIALSDLLIVFFCIPVTML 103
      | : | : | | : | : || : || : || : | : || || | | : || : || | : | :
Db      51 RVVLILAYCSIILLGVVGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCCLPFTLT 110

30 Qy      104 QNVSDTWLGGAFIGKMVPFVQCTAIVTEILTMTCIAVERHQGLVHPFKMKROYTNQRAFT 163
      : | | : | : || : | : : || : || : || : | : : : : | : |
Db      111 YTLMGWEWKMGPVLCFLVYPYAQGLAVQVSTVTLTVIALDRHRCIV--YHLDSKISKQNSFL 168

Qy      164 MLGVVWLVAIIIGSPM---WHVQRLEIKYDFLYEKEHICCLEEW---SSPVHQKIYTTFI 217
35 : || : | : : : || : : || : || | : | | : | : : || :
Db      169 IIGLAWGISALLASPLAIFREYSLIEIIPDF----EIVACTEKWPGECKSIYGTVYSLSS 224

Qy      218 LVTLFLLPLLLL SVLYGKIGYELW--IKKRIGDGSVLRTHGKEMFKIARKKKRAVIMMV 275
      | : | : || | : || | : | | : | : | : | : : : : | : |
40 Db      225 LLILYVLPLGIISVSIVRI----WSKLKNHVS PGAANDHYH-----QRRQKTTKMLV 272

Qy      276 TVVVLFVAVCWAPFHIVHMMIEYSNFE---KEYDEVTIKMFIFAIVQIIGFFNSICNPPIYA 332
      ||| : || | | | : : : : || | | : | | : : || : |
Db      273 FVVVVFVAVSWLPLHAFQLAVDIDSQVLDLKEY-----KLIFTVFHIIAMCSTFANPLL YG 327

45 Qy      333 LMNENFKKNFVSA 345
      || | : | | : ||
Db      328 WMNSNYRKAFLSA 340

50 ID      NY2R_BOVIN      STANDARD; PRT; 384 AA.
AC      P79113;
DT      01-NOV-1997 (Rel. 35, Created)
DT      01-NOV-1997 (Rel. 35, Last sequence update)
DT      30-MAY-2000 (Rel. 39, Last annotation update)

```


Art Unit: 1646

DE Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor).
 GN NPY2R.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 5 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 10 RA Ammar D.A., Kolakowski L.F. Jr., Eadie D.M., Wong D.J., Ma Y.Y.,
 RA Yang-Feng T.L., Thompson D.A.;
 RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
 CC -!- FUNCTION: RECEPTOR FOR NEUROPEPTIDE Y AND PEPTIDE YY.
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
 15 CC -!- SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.
 CC HIGHEST TO TACHYKININS RECEPTORS.
 CC -----
 -
 CC This SWISS-PROT entry is copyright. It is produced through a
 20 collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 -
 CC the European Bioinformatics Institute. There are no restrictions on
 its
 25 CC use by non-profit institutions as long as its content is in no
 way
 CC modified and this statement is not removed. Usage by and for
 commercial
 CC entities requires a license agreement (See [http://www.isb-](http://www.isb-sib.ch/announce/)
 30 [sib.ch/announce/](http://www.isb-sib.ch/announce/)
 CC or send an email to license@isb-sib.ch).
 CC -----
 -
 35 DR EMBL; U50144; AAB40600.1; -.
 DR InterPro; IPR000276; GPCR_Rhodpsn.
 DR Pfam; PF00001; 7tm_1; 1.
 DR PRINTS; PR00237; GPCRRHODOPSN.
 DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
 DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
 40 KW G-protein coupled receptor; Transmembrane; Glycoprotein;
 KW Phosphorylation; Lipoprotein; Palmitate.
 FT DOMAIN 1 52 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 53 75 1 (POTENTIAL).
 FT DOMAIN 76 85 CYTOPLASMIC (POTENTIAL).
 45 FT TRANSMEM 86 107 2 (POTENTIAL).
 FT DOMAIN 108 127 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 128 149 3 (POTENTIAL).
 FT DOMAIN 150 169 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 170 190 4 (POTENTIAL).
 50 FT DOMAIN 191 217 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 218 243 5 (POTENTIAL).
 FT DOMAIN 244 271 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 272 294 6 (POTENTIAL).
 FT DOMAIN 295 307 EXTRACELLULAR (POTENTIAL).

FT	TRANSMEM	308	331	7 (POTENTIAL).
FT	DOMAIN	332	384	CYTOPLASMIC (POTENTIAL).
FT	CARBOHYD	13	13	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	DISULFID	126	206	BY SIMILARITY.
FT	LIPID	345	345	PALMITATE (POTENTIAL).
SO	SEQUENCE	384 AA; 42943 MW; 468D19CBA8F29681 CRC64;		

Query Match 20.8%; Score 449; DB 1; Length 384;
Best Local Similarity 31.6%; Pred. No. 7.4e-25;
Matches 99; Conservative 74; Mismatches 106; Indels 34; Gaps

Db 53 OVVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCCLPFTLT 112

Db 113 YTLMG EWKMG PVLCHLVPYAQGLAVQVSTITLT VIALDRHRCIV--YHLESKISKQISFL 170

Db 171 IIGLAWGVSAALLASPLAIFREYSLIEIIPDF----EIVACTEKWPGEKGIYGTIYSLSS 226

Db 227 LLILYVLPLGIISFSYTRI---WSKLKNHVSPGAAHDHYH-----QRRQKTTKMLV 274

Db 275 CVVVVFAVSWLPLHAFQLAVDIDSHVLDLKEY-----KLFTVFHIIAMCSTFANPLLYG 329

Db 330 WMNSNYRKAFLSA 342

N;Alternate names: neuropeptide y/peptide YY receptor type 2

C;Species: Homo sapiens (man)

C;Date: 01-Mar-1996 #sequence revision 01-Mar-1996 #text change 20-Apr-2000

C;Accession: I39187; I39163; G02301

R;Gerald, C.; Walker, M.W.; Vaysse, P.J.

J. Biol. Chem. 270, 26758-26761, 1995

A;Title: Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype.

A;Reference number: I39187; MUID:96070760; PMID:7592910

A;Accession: I39187

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-381 <GER>

A;Cross-references: EMBL:U36269; NID:q1063633; PIDN:AAC50281.1; PID:q1063634

R; Rose, P.M.; Fernandes, P.; Lynch, J.S.; Frazier, S.T.; Fisher, S.M.;

Kodukula, K.; Kienzle, B.; Seethala, R.

Art Unit: 1646

; Patent No. 5989834
; GENERAL INFORMATION:
; APPLICANT: Synaptic Pharmaceutical Corporation
; TITLE OF INVENTION: NUCLEIC ACID ENCODING NEUROPEPTIDE
5 ; TITLE OF INVENTION: Y/PEPTIDE YY (Y2) RECEPTORS AND USES THEREOF
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
10 ; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
15 ; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
20 ; APPLICATION NUMBER: US/08/687,355A
; FILING DATE: No. 5989834ember 26, 1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
25 ; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 44742-A-PCT/JPW/MAT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-278-0400
; TELEFAX: 212-391-0525
30 ; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 381 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
35 ; MOLECULE TYPE: protein
US-08-687-355A-6

Query Match 21.1%; Score 454.5; DB 2; Length 381;
Best Local Similarity 30.1%; Pred. No. 3.7e-33;
40 Matches 104; Conservative 75; Mismatches 119; Indels 47; Gaps
10;

Qy 25 IAHYGLRPLVLTQPQLP-----ARARLALLVGMLIFALALFGNALVVYVTR 71
: || | :|| :: || | | : ||: ||: || :
45 Db 18 VEFYGSQPTTPRGELPPDPEPELIDSTKLVEVQVVLILAYCSIILLGVVGNLSLVIHVVIK 77

Qy 72 SKAMRTVTNIFICSLLSDLLIVFFCIPVTMLQNVSDTWLGGAFICKMVPFVQCTAIVTE 131
|: ||||| || :||: ||| : | | : | :||: | |:
Db 78 FKSMTVTNFFIANLAVADLLVNTLCPLFTLTITLMGEWKMGFVLCHLVPYAQGLAVQVS 137
50
Qy 132 ILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPM---WHVQRLEIK 188
: ||: ||: ||: :| : : : | :| :||: | | : : || : ||
Db 138 TITLTVIALDRHRCIV--YHLESKISKQISFLIIGLAWGVSALLASPLAIFREYSLEII 195

Art Unit: 1646

Qy 189 YDFLYEKEHICCLEEW---SSPVHQKIYTTFILVTLFLLPLLLLSVLYGKIGYELW--IK 243
|| | : | | : | : : | : | : | : | : | : | : |

Db 196 PDF----EIVACTEKWPGEKSVYGTVYSLSTLLILYVLPLGIISFSYTRI----WSKLK 247

5 Qy 244 KRIGDGSVLRTHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIVHMMIEYSNFE-- 301
: | : | : : : | : | | : | | | : : : :

Db 248 NHVSPGAASDHYH-----QRRHKMTKMLVCVVVFAVSWLPLHAFQLAVDIDSHVLD 299

Qy 302 -KEYDEVTIKMIFAIVQIIGFFNSICNPIIYALMNENFKKNFVSA 345

10 ||| | : | : | : : | : : | | | : : | | : |

Db 300 LKEY-----KLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSA 339

Art Unit: 1646

```
; Sequence 2, Application US/09899532
; Patent No. US20020048791A1
; GENERAL INFORMATION:
5 ; APPLICANT: Bloomquist, Brian T.
; APPLICANT: Zhelnin, Leonid
; TITLE OF INVENTION: Human Neuropeptide Y-Like G
; TITLE OF INVENTION: Protein-Coupled Receptor
; FILE REFERENCE: 02973.00040
10 ; CURRENT APPLICATION NUMBER: US/09/899,532
; CURRENT FILING DATE: 2001-07-06
; PRIOR APPLICATION NUMBER: US 60/216,523
; PRIOR FILING DATE: 2000-07-06
; NUMBER OF SEQ ID NOS: 3
15 ; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 431
; TYPE: PRT
; ORGANISM: Homo sapiens
20 US-09-899-532-2

Query Match      81.8%; Score 1767; DB 9; Length 431;
Best Local Similarity 80.1%; Pred. No. 7.3e-156;
Matches 339; Conservative 36; Mismatches 38; Indels 10; Gaps
25 3;

Qy      4 NLTAEQLSALLRLHNLTRAQFIAHYGLRPLVLTTPQLPARARLALLLVGMLIFALALFGNA 63
      | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      5 NITPEQFSRLLRDHNLTREQFIALYRLRPLVYTPELPGRAKLALVLTGVLI FALALFGNA 64

30 Qy      64 LVVYVTRSKAMRTVTNIFICS LALSDLLIVFFCIPVTMLQNVS DTLWGGA FICKMVPFV 123
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      65 LVFYVTRSKAMRTVTNIFICS LALSDLLITFFCIPVTMLQNI SDNLWGGA FICKMVPFV 124

35 Qy      124 QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ 183
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      125 QSTAVVTEILTMTCIAVERHQGLVHPFKMKWQYTNRRRAFTMLGVVWLVAIVIGSPMWHVQ 184

40 Qy      184 RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSVLYGKIGYELWIK 243
      : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      185 QLEIKYDFLYEKEHICCLEEWTS PVHQKIYTTFILVILFLLPLMVMLILYSKIGYELWIK 244

Qy      244 KRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIVHMMIEYSNFEKE 303
      | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
45 Db      245 KRVGDGSVLRTIHGKEMSKIARKKKRAVIMMVTVVVLFVAVCWAPFHVHMMIEYSNFEKE 304

Qy      304 YDEVTIKMIFAIVQIIGFFNSICNP IYALMNENFKKNFVS AVCYCIVKETPSSARKHGS 363
      | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      305 YDDVTIKMIFAIVQIIGFSNSICNP IYAFMNENFKKNVLS AVCYCIVNKTFS PAQRHGN 364

50 Qy      364 SGAMVMHRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKKR-----RSKVA-S 413
      | | : | : | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      365 SGITMMRKAKFSLREN PVEETKGEAFSDGNIEVKLCEQTEEEKKKLKRHLALFRSELAEN 424
```


Art Unit: 1646

Db 65 LVFYVWTRSKAMRTVTNIFICS LALS DLLITFFCIPVTMLQNISDNWLGGAFICKMVPFV 124

Qy 124 QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ 183
| | : | | : | | | | | | | | | | | | | | | | | : | | | | | | | | : | | | | | |

5 Db 125 QSTAVVTEMLTMTCIAVERHQGLVHPFKMKWQYTNRRRAFTMLGVVWLVAIVIGSPMWHVQ 184

Qy 184 RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSVLYGKIGYELWIK 243
: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | : | | | | | | | |

10 Db 185 QLEIKYDFLYEKEHICCLEEWTSPPVHQKIYTTFILVILFLLPLMVMLILYSKIGYELWIK 244

Qy 244 KRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHIVHMMIEYSNFEKE 303
| | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Db 245 KRVGDGSVLRTIHGKEMSKIARKKKRAVIMMVTVVALFVAVCWAPFHVHMMIEYSNFEKE 304

15 Qy 304 YDEVTIKMIFAIVQIIGFFNSICNP IYALMNNENFKKNFVSAVCYCIVKETPSSARKHGS 363
| | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Db 305 YDDVTIKMIFAIVQIIGFSNSICNP IYAFMNNENFKKNVLSAVCYCIVNKTFSPAQRHGN 364

Qy 364 SGAMVMHRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKKR-----RSKVA-S 413
| | : | : | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |

20 Db 365 SGITMMRKKAKFSLREN PVEETKGEAFSDGNIEVKLCEQTEEEKKKLKRHLALFRSELAEN 424

Qy 414 CPL 416
| |

25 Db 425 SPL 427

LOCUS AK048439 2864 bp mRNA linear HTC 05-DEC-2002

30 DEFINITION Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130060K24 product:hypothetical Rhodopsin-like GPCR superfamily containing protein, full insert sequence.

ACCESSION AK048439

VERSION AK048439.1 GI:26339331

35 KEYWORDS HTC; CAP trapper.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

40 REFERENCE 1

AUTHORS Carninci,P. and Hayashizaki,Y.

TITLE High-efficiency full-length cDNA cloning

JOURNAL Meth. Enzymol. 303, 19-44 (1999)

MEDLINE 99279253

45 PUBMED 10349636

REFERENCE 2

AUTHORS Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.

TITLE Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new

50 genes

JOURNAL Genome Res. 10 (10), 1617-1630 (2000)

Art Unit: 1646

MEDLINE 20499374
PUBMED 11042159
REFERENCE 3
AUTHORS Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N.,
5 Carninci,P.,
Konno,H., Akiyama,J., Nishi,K., Kitsunai,T., Tashiro,H., Itoh,M.,
Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A.,
Yamamoto,R., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kashiwagi,K.,
10 Fujiwake,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watahiki,M.,
Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S.,
Kawai,J.,
Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.
TITLE RIKEN integrated sequence analysis (RISA) system--384-format
sequencing pipeline with 384 multicapillary sequencer
15 JOURNAL Genome Res. 10 (11), 1757-1771 (2000)
MEDLINE 20530913
PUBMED 11076861
REFERENCE 4
AUTHORS Kawai,J., Shinagawa,A., Shibata,K., Yoshino,M., Itoh,M., Ishii,Y.,
20 Arakawa,T., Hara,A., Fukunishi,Y., Konno,H., Adachi,J., Fukuda,S.,
Aizawa,K., Izawa,M., Nishi,K., Kiyosawa,H., Kondo,S., Yamanaka,I.,
Saito,T., Okazaki,Y., Gojobori,T., Bono,H., Kasukawa,T., Saito,R.,
Kadota,K., Matsuda,H., Ashburner,M., Batalov,S., Casavant,T.,
25 Fleischmann,W., Gaasterland,T., Gissi,C., King,B., Kochiwa,H.,
Kuehl,P., Lewis,S., Matsuo,Y., Nikaido,I., Pesole,G.,
Quackenbush,J., Schriml,L.M., Staubli,F., Suzuki,R., Tomita,M.,
Wagner,L., Washio,T., Sakai,K., Okido,T., Furuno,M., Aono,H.,
Baldarelli,R., Barsh,G., Blake,J., Boffelli,D., Bojunga,N.,
30 Carninci,P., de Bonaldo,M.F., Brownstein,M.J., Bult,C.,
Fletcher,C., Fujita,M., Gariboldi,M., Gustincich,S., Hill,D.,
Hofmann,M., Hume,D.A., Kamiya,M., Lee,N.H., Lyons,P.,
Marchionni,L., Mashima,J., Mazzarelli,J., Mombaerts,P.,
Nordone,P.,
35 Ring,B., Ringwald,M., Rodriguez,I., Sakamoto,N., Sasaki,H.,
Sato,K., Schonbach,C., Seya,T., Shibata,Y., Storch,K.F.,
Suzuki,H.,
Toyo-oka,K., Wang,K.H., Weitz,C., Whittaker,C., Wilming,L.,
Wynshaw-Boris,A., Yoshida,K., Hasegawa,Y., Kawaji,H., Kohtsuki,S.
and Hayashizaki,Y.
40 TITLE Functional annotation of a full-length mouse cDNA collection
JOURNAL Nature 409 (6821), 685-690 (2001)
MEDLINE 21085660
PUBMED 11217851
REFERENCE 5
45 AUTHORS The FANTOM Consortium and the RIKEN Genome Exploration Research
Group Phase I & II Team.
TITLE Analysis of the mouse transcriptome based on functional annotation
of 60,770 full-length cDNAs
JOURNAL Nature 420, 563-573 (2002)
50 REFERENCE 6 (bases 1 to 2864)
AUTHORS Adachi,J., Aizawa,K., Akimura,T., Arakawa,T., Bono,H.,
Carninci,P.,
Fukuda,S., Furuno,M., Hanagaki,T., Hara,A., Hashizume,W.,
Hayashida,K., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T.,

Art Unit: 1646

5 Hori, F., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kasukawa, T.,
Kato, H., Kawai, J., Kojima, Y., Kondo, S., Konno, H., Kouda, M.,
Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M.,
Nakamura, M., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Ohsato, N.,
Okazaki, Y., Saito, R., Saitoh, H., Sakai, C., Sakai, K., Sakazume, N.,
Sano, H., Sasaki, D., Shibata, K., Shinagawa, A., Shiraki, T.,
Sogabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Akahira, S.,
Takeda, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A.,
Muramatsu, M. and Hayashizaki, Y.

10 TITLE Direct Submission
JOURNAL Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of
Physical and Chemical Research (RIKEN), Laboratory for Genome
Exploration Research Group, RIKEN Genomic Sciences Center (GSC),
RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku,

15 Yokohama,
Kanagawa 230-0045, Japan (E-mail: genome-res@gsc.riken.go.jp,
URL: <http://genome.gsc.riken.go.jp/>, Tel: 81-45-503-9222,
Fax: 81-45-503-9216)

20 COMMENT cDNA library was prepared and sequenced in Mouse Genome
Encyclopedia Project of Genome Exploration Research Group in Riken
Genomic Sciences Center and Genome Science Laboratory in RIKEN.
Division of Experimental Animal Research in Riken contributed to
prepare mouse tissues.
Please visit our web site for further details.

25 URL: <http://genome.gsc.riken.go.jp/>
URL: <http://fantom.gsc.riken.go.jp/>.

FEATURES Location/Qualifiers
source 1. .2864
/organism="Mus musculus"
30 /mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="FANTOM_DB:C130060K24"
/db_xref="taxon:10090"
/clone="C130060K24"
35 /tissue_type="head"
/clone_lib="RIKEN full-length enriched mouse cDNA
library"
/dev_stage="16 days embryo"
CDS 64. .1161
40 /note="unnamed protein product; hypothetical
Rhodopsin-like GPCR superfamily containing protein
(InterPro|IPR000276, evidence: InterPro)
putative"
/codon_start=1
45 /protein_id="BAC33337.1"
/db_xref="GI:26339332"

/translation="MLIFALALFGNALVVYVTRSKAMRTVTNIFICSLALSDLLIVE
50 FCIPVTMLQNVSDTWLGGAFICKMVPFVQCTAIVTEILTMTCIAVERHQGLVHPFKMK
RQYTNQRAFTMLGVVWLVAIIIGSPMWHVQRLEIKYDFLYEKEHICCLEEWSSPVHQK
IYTTFILVTLFLLPLLLSVLYGKIGYELWIKKRIGDGSVLRITHGKEMFKIARKKKR

Art Unit: 1646

AVIMMVTVVVLFVAVCWAPFHIVHMMIEYSNFEKEYDEVTIKMIFAIVQIIGFFNSICN

PIIYALMNNENFKKNFVSAVCYCIVKETPSSARKHGSSGAMVMHRRAKLAARENPFVEIK
GEAFGGSNIDIKWCEQPEKKRRRSKVASCPL"

5

BASE COUNT 839 a 609 c 602 g 814 t
ORIGIN10 Query Match 94.9%; Score 1681; DB 11; Length 2864;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1681; Conservative 0; Mismatches 0; Indels 0; Gaps
0;15 Qy 92 GGCCACTGGTGCTCACCCCGCAGCTTCCCGCGCGGCCAGGCTGGCCCTCCTGCTGGTTCG 151
|||||
Db 2 GGCCACTGGTGCTCACCCCGCAGCTTCCCGCGCGGCCAGGCTGGCCCTCCTGCTGGTTCG 6120 Qy 152 GCATGCTCATCTTTGCCCTGGCGCTCTTCGGCAACGCCCTGGTAGTCTATGTGGTGACCC 211
|||||
Db 62 GCATGCTCATCTTTGCCCTGGCGCTCTTCGGCAACGCCCTGGTAGTCTATGTGGTGACCC 12125 Qy 212 GCAGCAAGGCCATGCGCACCGTCACCAACATCTTCATCTGCTCCCTGGCACTCAGCGACC 271
|||||
Db 122 GCAGCAAGGCCATGCGCACCGTCACCAACATCTTCATCTGCTCCCTGGCACTCAGCGACC 181Qy 272 TGCTCATCGTCTTCTTCTGCATCCCGGTACCATGCTCCAGAACGTCTCGGACACCTGGC 331
|||||
Db 182 TGCTCATCGTCTTCTTCTGCATCCCGGTACCATGCTCCAGAACGTCTCGGACACCTGGC 24130 Qy 332 TGGGGGGTGCCTTCATTTGCAAAATGGTCCCATTTGTCCAGTGCACTGCCATTGTGACAG 391
|||||
Db 242 TGGGGGGTGCCTTCATTTGCAAAATGGTCCCATTTGTCCAGTGCACTGCCATTGTGACAG 30135 Qy 392 AAATCCTTACTATGACCTGCATTGCTGTGAAAGGCACCAGGGACTTGTCCATCCTTTTA 451
|||||
Db 302 AAATCCTTACTATGACCTGCATTGCTGTGAAAGGCACCAGGGACTTGTCCATCCTTTTA 36140 Qy 452 AAATGAAGCGGCAGTACACCAATCAAAGAGCTTTCACAATGCTAGGTGTGGTGTGGCTGG 511
|||||
Db 362 AAATGAAGCGGCAGTACACCAATCAAAGAGCTTTCACAATGCTAGGTGTGGTGTGGCTGG 42145 Qy 512 TGGCCATCATCATAGGATCACCCATGTGGCATGTGCAGCGACTTGAGATTAAGTATGACT 571
|||||
Db 422 TGGCCATCATCATAGGATCACCCATGTGGCATGTGCAGCGACTTGAGATTAAGTATGACT 481Qy 572 TCCTATATGAAAAAGAACACATCTGCTGCCTGGAAGAGTGGAGCAGCCCCGTGCACCAGA 631
|||||
Db 482 TCCTATATGAAAAAGAACACATCTGCTGCCTGGAAGAGTGGAGCAGCCCCGTGCACCAGA 54150 Qy 632 AGATCTACACCACCTTCATCCTTGTACCCCTCTTCCTGCTACCACTGTTGCTGCTCTCTG 691
|||||
Db 542 AGATCTACACCACCTTCATCCTTGTACCCCTCTTCCTGCTACCACTGTTGCTGCTCTCTG 601

Qy 692 TCCTCTACGGGAAAATCGGTTATGAGCTTTGGATCAAGAAAAGAAATCGGGGATGGCTCAG 751

Art Unit: 1646

	Qy	1352	AAAAGCCAGAGAGCTTTCATATTAAAAATGTTGACAAACACTCAGAAGGCAGGGACAGGG
	1411		
5	Db	1262	AAAAGCCAGAGAGCTTTCATATTAAAAATGTTGACAAACACTCAGAAGGCAGGGACAGGG
	1321		
	Qy	1412	GATTCAAGAGTTTAAAGTCATCCTTAGCTGCACGATAAGTTTGAGGATAACCTGGGCTAC
	1471		
10	Db	1322	GATTCAAGAGTTTAAAGTCATCCTTAGCTGCACGATAAGTTTGAGGATAACCTGGGCTAC
	1381		
	Qy	1472	AAGAGACCCTGTCTCAAGAAGCCATAATAATTAAAACAACCATCCTTAACTAATGATAAT
	1531		
15	Db	1382	AAGAGACCCTGTCTCAAGAAGCCATAATAATTAAAACAACCATCCTTAACTAATGATAAT
	1441		
	Qy	1532	GACAAAGTATTTTCCATTGAAAATACATGTAAGCTGCAATTTTGAAAAATTATTGAACC
	1591		
20	Db	1442	GACAAAGTATTTTCCATTGAAAATACATGTAAGCTGCAATTTTGAAAAATTATTGAACC
	1501		
	Qy	1592	ACCCTTGTGATTAATAGATGAAGTTAAAAAAATTTAAATGTGTTTTATTGTATGTATA
	1651		
25	Db	1502	ACCCTTGTGATTAATAGATGAAGTTAAAAAAATTTAAATGTGTTTTATTGTATGTATA
	1561		
30	Qy	1652	TGGTTGGTTTACCTGTGTATATGTCTTTCAGTAACTTGATATAAACTCAATGATCTCAGC
	1711		
35	Db	1562	TGGTTGGTTTACCTGTGTATATGTCTTTCAGTAACTTGATATAAACTCAATGATCTCAGC
	1621		
	Qy	1712	TAGTAACTTTCCTTCTGTGTGGTCAATGTGATATGATTTCCCTATATATTGCTAAATTGAAT
	1771		
40	Db	1622	TAGTAACTTTCCTTCTGTGTGGTCAATGTGATATGATTTCCCTATATATTGCTAAATTGAAT
	1681		
	Qy	1772	G 1772
45	Db	1682	G 1682

Art Unit: 1646

RESULT 5

US-10-272-983-38

; Sequence 38, Application US/10272983

; Publication No. US20030148450A1

; GENERAL INFORMATION:

; APPLICANT: Chen, Ruoping

; APPLICANT: Dang, Huong T.

; APPLICANT: Liaw, Chen W.

; APPLICANT: Lin, I-Lin

; TITLE OF INVENTION: Human Orphan G Protein Coupled Receptors

; FILE REFERENCE: AREN0050

; CURRENT APPLICATION NUMBER: US/10/272,983

; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: US/09/417,044

; PRIOR FILING DATE: 1999-10-12

; PRIOR APPLICATION NUMBER: 60/109,213

; PRIOR FILING DATE: 1998-11-20

; PRIOR APPLICATION NUMBER: 60/120,416

; PRIOR FILING DATE: 1999-02-16

; PRIOR APPLICATION NUMBER: 60/121,851

; PRIOR FILING DATE: 1999-02-26

; PRIOR APPLICATION NUMBER: 60/123,946

; PRIOR FILING DATE: 1999-03-12

; PRIOR APPLICATION NUMBER: 60/123,949

; PRIOR FILING DATE: 1999-03-12

; PRIOR APPLICATION NUMBER: 60/136,436

; PRIOR FILING DATE: 1999-05-28

; PRIOR APPLICATION NUMBER: 60/136,437

; PRIOR FILING DATE: 1999-05-28

; PRIOR APPLICATION NUMBER: 60/136,439

; PRIOR FILING DATE: 1999-05-28

; PRIOR APPLICATION NUMBER: 60/136,567

; PRIOR FILING DATE: 1999-05-28

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 74

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 38

; LENGTH: 431

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-272-983-38

Query Match 81.7%; Score 1764; DB 12; Length 431;

Best Local Similarity 79.9%; Pred. No. 1.4e-155;

Matches 338; Conservative 37; Mismatches 38; Indels 10; Gaps

3;

Qy 4 NLTAEQLSALLRLHNLTRAQFIAHYGLRPLVLTPOLPARARLALLLVGMLIFALALFGNA 63

|:| || | ||| |||| | |||| | ||:| ||:| ||:| | |:| ||||| |||||

Db 5 NITPEQFSRLLRDHNLTREQFIALYRLRPLVYTPELPGRAKLALVLTGVLIFALALFGNA 64

Qy 64 LVVYVTRSKAMRTVTNIFICSLALSDLLIVFFCIPVTMLQNVS DTWLGGAFICKMVPFV 123

|| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Art Unit: 1646

Db 65 LVFYVTRSKAMRTVTNIFICSLALSDLLITFFCIPVTMLQNISDNWLGGAFICKMVPFV 124

Qy 124 QCTAIVTEILTMTCIAVERHQGLVHPFKMKRQYTNQRAFTMLGVVWLVAIIIGSPMWHVQ 183
| | : | | : | | | | | | | | | | | | | | | | | | : | | | | | | | | : | | | | | |

5 Db 125 QSTAVVTEMLTMTCIAVERHQGLVHPFKMKWQYTNRRRAFTMLGVVWLVAIVIVGSPMWHVQ 184

Qy 184 RLEIKYDFLYEKEHICCLEEWSSPVHQKIYTTFILVTLFLLPLLLLSVLYGKIGYELWIK 243
: | | | | | | | | | | | | : | | | | | | | | | | | | | | : : : | | | | | | | |

10 Db 185 QLEIKYDFLYEKEHICCLEEWTSPVHQKIYTTFILVILFLLPLMVMLILYSKIGYELWIK 244

Qy 244 KRIGDGSVLRTIHGKEMFKIARKKKRAVIMMVTVVVLFVAVCWAPFHVHMMIEYSNFEKE 303
| | : | | | | | | | | | | | | | | | | | | | | | : | | | | | | | | | | | |

Db 245 KRVGDGSVLRTIHGKEMSKIARKKKRAVIMMVTVVALFVAVCWAPFHVHMMIEYSNFEKE 304

15 Qy 304 YDEVTIKMIFAIVQIIGFFNSICNPIIYALMNENFKKNFVSAVCYCIVKETPSSARKHGS 363
| | : | | | | | | | | | | | | | | | | | : | | | | | | | | : | | | | | : | | : | | : |

Db 305 YDDVTIKMIFAIVQIIGFSNSICNPIVYAFMNENFKKNVLSAVCYCIVNKTFSQAQRHGN 364

Qy 364 SGAMVMHRRAKLAARENPV-EIKGEAFGGSNIDIKWCEQPEKKKR-----RSKVA-S 413
| | : | : | | : | | | | | | | | | | | | : | | | | | | : | | | | : | | : | | : |

20 Db 365 SGITMMRKKAKFSLRENPEETKGEAFSDGNIEVKLCEQTEKKKKLKRHLALFRSELAEN 424

Qy 414 CPL 416
| |

25 Db 425 SPL 427